Radiopharm Theranostics Limited Sponsored ADR(RADX)
$0.69+0.01 (+2.09%)
RADX
Radiopharm Theranostics Limited Sponsored ADR earnings date
$0.69
At close:+0.01 (+2.09%)
Want to see RADX full AI Analyst Report?
Radiopharm Theranostics Limited Sponsored ADR (RADX) Q4 2026 Earnings Report
65 Followers
RADX Q4 2026 EPS Results
- Actual EPS
- -$1.68
- Consensus EPS
- -$2.56
- Beat/Miss
- Beat by +$0.88
- One Year Ago EPS
- -$1.95
RADX Q4 2026 Revenue Results
- Actual Revenue
- $971.15K
- Expected Revenue
- $1.44M
- Beat/Miss
- Missed by -$469.85K
- YoY Revenue Growth
- -31.95%
Earnings Announcement Details
- Quarter
- Q4 2026
- Date
- 08/28/2026
- Time
- Before Open
- Conference Call
- Friday, August 28, 2026
RADX Upcoming Earnings
Radiopharm Theranostics Limited Sponsored ADR's next earnings date is estimated for February 26, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q4 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2026 Earnings Call Summary
No earnings call summary is available for this earnings event.
RADX Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 26, 2027 | 2027 (Q2) | -1.05- | -2.11 | ― | ― |
| Aug 28, 2026 | 2026 (Q4) | -2.56-1.68 | -1.95 | 14.14% (+0.28) | |
| Feb 27, 2026 | 2026 (Q2) | -2.10-2.11 | -1.94 | -8.56% (-0.17) | |
| Sep 16, 2025 | 2025 (Q4) | -1.96-1.95 | -10.26 | 80.97% (+8.30) | |
| Feb 28, 2025 | 2025 (Q2) | -1.97-1.94 | -14.1 | 86.24% (+12.16) | |
| Aug 29, 2024 | 2024 (Q4) | -2.00-10.26 | -12.44 | 17.57% (+2.19) | |
| Feb 29, 2024 | 2024 (Q2) | -2.02-14.10 | -5.69 | -147.59% (-8.40) | |
| Aug 31, 2023 | 2023 (Q4) | -3.79-12.44 | -1.47 | -748.84% (-10.98) | |
| Feb 28, 2023 | 2023 (Q2) | ―-5.69 | -31.83 | 82.11% (+26.14) | |
| Sep 30, 2022 | 2022 (Q4) | ―-1.47 | ― | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

